The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
CNS Clinical Trials: Suicidality and Data Collection - Workshop Summary
emergence of suicidal ideation and suicidal behavior. His interest in ventricular repolarization derives from work with academic collaborators on the characterization of multiple cardiac ion channel blockade by antipsychotics beginning in 1995 and the design of one of the first “Thorough QT Studies” required for regulatory approval of Cialis in 2000.
During his 21 years in industry with Lilly, he has authored over 80 peer-reviewed publications. He is an inventor on eight patents of Lilly products. He has extensive experience interacting with multiple divisions of the FDA, European regulatory authorities, and Japanese regulatory authorities. He is a member of the American Osteopathic Association, the American Psychiatric Association, the American Society for Clinical Psychopharmacology, the American College of Psychiatrists, the American College of Neuropsychopharmacology, and the American Federation for Clinical Research. He is also a fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of the United Kingdom and member of the American Academy of Pharmaceutical Physicians.
David Brent, M.D., was born in Rochester, New York, and grew up in the Philadelphia area. He received his undergraduate education at Pennsylvania State University and graduated from Jefferson Medical College of Thomas Jefferson University. Dr. Brent trained in pediatrics at the University of Colorado and in general and child psychiatry at Western Psychiatric Institute and Clinic and completed a master’s degree in psychiatric epidemiology at the University of Pittsburgh School of Public Health. He is currently academic chief, child and adolescent psychiatry, at Western Psychiatric Institute and Clinic and professor of psychiatry, pediatrics and epidemiology, University of Pittsburgh School Medical Center. He cofounded and now directs Services for Teens at Risk (STAR), a commonwealth of Pennsylvania–funded program for suicide prevention, education of professionals, and the treatment of at-risk youth and their families. His work in the area of suicide has focused on the epidemiology of adolescent suicide and has helped to identify the role of firearms, substance abuse, and affective disorders as risk factors for youth suicide.
Consequently, he and colleagues at Western Psychiatric Institute and Clinic have helped to establish the role of cognitive therapy as a treatment for depressed adolescents in an NIMH-funded clinical trial. Dr. Brent has also focused on the familial and genetic aspects of suicide, having found that suicidal behavior clusters in families, and is currently, along with colleagues at New York State Psychiatric Institute, studying how suicidal behavior may be transmitted from parent to child. His work has been funded by the William T. Grant Foundation and the National